Skip to main content
. Author manuscript; available in PMC: 2016 Jun 30.
Published in final edited form as: Bioorg Med Chem. 2006 Oct 11;14(24):8495–8505. doi: 10.1016/j.bmc.2006.08.042

Table 4.

Anti-cancer data

1° Screening Prostate
DU-145
(μM)
Ovary
IGROV-ET
(μM)
Breast
SK-BR3
(μM)
Melanoma
SK-MEL-28
(μM)
Lung
A549
(μM)
Leukemia
K-562
(μM)
Pancreas
PANC1
(μM)
Colon
LOVO
(μM)
Cervix
HELA-APL
(μM)
3 GI50 >28.9 13.8 >28.9 15.9 >28.9 15.0 8.5 10.4 14.3
TGI >28.9 >28.9 >28.9 >28.9 >28.9 20.2 24.3 28.9 >28.9
LC50 >28.9 >28.9 >28.9 >28.9 >28.9 27.0 28.9 >28.9 >28.9
4 GI50 5.4 4.1 7.3 5.3 5.5 6.0 3.2 4.3 4.8
TGI 9.2 8.4 14.4 9.1 9.5 9.6 6.6 8.3 8.9
LC50 15.8 17.1 17.8 15.5 16.5 15.3 13.4 16.3 16.5
5 GI50 13.5 9.6 9.4 7.5 9.6 10.0 4.8 5.1 6.9
TGI >28.5 >28.5 20.8 23.2 25.2 14.3 9.3 11.9 17.9
LC50 >28.5 >28.5 >28.5 >28.5 >28.5 20.3 18.3 27.6 >28.5
6 GI50 15.8 10.7 9.3 4.8 12.2 7.1 5.1 4.9 10.0
TGI >27.1 >27.1 18.3 9.1 >27.1 11.0 10.8 11.4 27.1
LC50 >27.1 >27.1 >27.1 17.1 >27.1 17.1 23.1 26.4 >27.1
7 GI50 6.9 5.7 6.2 4.9 6.1 8.8 4.6 4.6 5.7
TGI 15.0 10.0 11.0 8.4 12.5 12.5 8.3 8.3 10.8
LC50 >27.1 17.4 19.5 14.3 25.4 17.9 15.0 14.9 20.2
8 GI50 >30.5 25.7 >30.5 29.4 >30.5 26.5 14.1 18.1 30.5
TGI >30.5 >30.5 >30.5 >30.5 >30.5 >30.5 >30.5 >30.5 >30.5
LC50 >30.5 >30.5 >30.5 >30.5 >30.5 >30.5 >30.5 >30.5 >30.5
9 GI50 8.3 9.2 10.4 5.6 9.6 7.9 5.4 7.5 6.8
TGI 18.9 18.2 >26.4 9.5 26.4 11.8 9.3 15.2 12.4
LC50 >26.4 >26.4 >26.4 16.2 >26.4 17.9 16.0 >26.4 22.7
10 GI50 4.8 3.4 5.0 5.0 5.0 6.4 2.8 3.5 4.5
TGI 8.4 6.8 8.6 8.7 9.0 10.0 6.1 7.0 8.3
LC50 14.7 13.8 14.8 15.1 16.2 15.6 13.0 13.8 15.2
11 GI50 14.8 10.8 15.8 9.8 >28.9 8.1 5.3 7.9 6.6
TGI >28.9 >28.9 >28.9 28.9 >28.9 13.4 9.9 17.6 14.0
LC50 >28.9 >28.9 >28.9 >28.9 >28.9 22.2 18.4 >28.9 28.9
12 GI50 5.6 4.4 11.3 4.2 11.9 2.8 3.1 3.0 3.8
TGI 14,1 9.0 24.0 7.9 >24.0 5.6 6.3 6.2 8.3
LC50 >24.0 18.3 >24.0 15.0 >24.0 11.0 12.9 12.8 17.8
13 GI50 4.4 8.1 7.3 3.9 4.7 1.7 2.8 2.9 3.6
TGI 8.0 12.0 11.2 7.4 8.3 4.3 5.9 5.9 7.0
LC50 14.4 17.8 17.3 14.0 14.5 9.8 12.4 12.2 13.6
14 GI50 3.8 2.9 6.5 3.0 4.5 0.1 1.1 1.5 1.0
TGI 7.6 6.1 10.1 6.0 8.0 0.5 3.7 4.5 3.3
LC50 15.5 12.6 15.8 12.0 14.3 1.1 9.6 10.8 9.2
15 GI50 >27.1 16.2 21.9 10.5 27.1 3.6 6.0 9.4 13.9
TGI >27.1 >27.1 >27.1 27.1 >27.1 7.5 13.4 27.1 >27.1
LC50 >27.1 >27.1 >27.1 >27.1 >27.1 15.5 >27.1 >27.1 >27.1
16 GI50 6.2 5.8 6.5 4.9 5.8 5.8 3.8 3.4 4.8
TGI 10.7 10.5 10.7 8.8 10.8 9.6 7.6 6.9 8.9
LC50 18.6 18.9 17.8 15.6 20.3 15.9 14.8 14.0 16.6
17 GI50 4.9 4.3 5.8 4.8 4.9 1.9 2.8 3.2 4.7
TGI 8.7 7.9 9.5 8.4 8.6 4.2 6.0 6.5 8.2
LC50 15.0 14.6 15.5 14.5 15.0 9.6 12.4 13.1 14.4
18 GI50 >30.7 23.2 >30.7 27.0 28.2 >30.7 16.8 12.3 30.7
TGI >30.7 >30.7 >30.7 >30.7 >30.7 >30.7 >30.7 >30.7 >30.7
LC50 >30.7 >30.7 >30.7 >30.7 >30.7 >30.7 >30.7 >30.7 >30.7
19 GI50 3.6 9.1 5.6 3.7 7.4 5.7 3.1 3.2 3.6
TGI 6.4 >20.3 10.2 6.5 20.3 8.6 5.8 5.9 6.6
LC50 11.3 >20.3 18.4 11.4 >20.3 13.0 10.8 10.9 11.9
20 GI50 9.1 4.9 6.9 4.8 6.1 4.4 4.4 4.5 4.9
TGI 24.3 8.9 12.1 8.7 10.9 8.0 8.3 8.1 8.9
LC50 >28.0 16.2 21.1 15.5 19.3 14.6 15.6 14.6 16.3
21 GI50 19.5 11.0 >27.6 6.1 20.8 6.7 5.2 5.0 5.7
TGI >27.6 25.6 >27.6 11.5 >27.6 12.6 10.5 9.4 10.4
LC50 >27.6 >27.6 >27.6 21.6 >27.6 23.8 21.2 17.7 18.9

GI50 is the concentration at which 50% growth inhibition was observed. TGI is the concentration at which total growth inhibition was observed. LC50 is the lethal concentration at which 50% cell death occurred.